Imagine a vaccine that doesn't fight a virus, but instead teaches your body to stop attacking its own joints. It targets a specific protein that causes inflammation, acting like a biological switch to turn off the damage. Instead of just masking the pain with pills, it helps the body repair itself and stop the disease from getting worse.
Osteoarthritis currently has no cure, with existing treatments only masking pain while joint damage progresses. This creates a massive healthcare burden affecting 300 million people and costing 0.5% of global GDP.
An active immunotherapy targeting IL-6. The project is delivering a Phase 2 clinical trial to prove the therapy can halt inflammation-driven cartilage destruction.
If you are a biotech drug developer dealing with the lack of curative OA treatments — this project developed an active immunotherapy that could become the first disease-modifying treatment for OA. It targets IL-6 to halt and reverse joint damage rather than just suppressing symptoms.
If you are a clinic dealing with patients who only find temporary relief from pain medication — this project developed a vaccine-like therapy that addresses OA at earlier stages. This increases successful clinical outcomes by stopping disease progression early.
If you are an insurer dealing with high healthcare costs and GDP losses from chronic disability — this project developed a treatment that costs 5-10% of conventional immunotherapies. This significantly reduces the long-term financial burden of treating 300 million affected people.
The treatment is expected to cost 5-10% of conventional immunotherapies because it uses inexpensive, immunogenic peptides to stimulate the patient's own antibodies. This is based on the project objective.
The project aims to implement a Phase II clinical trial to make the therapy out-licensing ready. Based on available project data, the goal is to prepare the asset for commercial transfer.
A phase 1 clinical trial was performed on 24 patients with Knee OA, showing a very good safety profile and anti-IL-6 antibody detection in over 95% of patients. Based on available project data, it is now moving to Phase 2.
The project period runs from 2024-03-01 to 2026-02-28. This window is used to demonstrate clinical proof of concept via Phase 2 trials.
Unlike current treatments that only offer pain relief, this therapy is designed to be a disease-modifying treatment that can be applied at earlier disease stages to stop progression.
The project is led by a single SME, PEPTINOV, based in France. With a 100% industry ratio and a total EU contribution of EUR 2,499,999, the structure is lean and focused on rapid commercialization. The absence of university partners suggests the core research is already internalized, and the funding is specifically targeted at clinical validation (Phase 2) to reach an out-licensing stage.
Contact PEPTINOV in France regarding the Anti-IL-6 Phase 2 trial results.
Contact us to explore licensing opportunities for this disease-modifying OA therapy.
